Clinical Trial Update: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing bb2121 to standard regimens in relapsed/refractory multiple myeloma; completed study evaluating efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• bb2121 (idecabtagene vicleucel)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED